Oncotarget

Drs. Kerri Winters-Stone and Jacob Raber discuss their study on how APOE genotype affects cancer survivors' response to exercise interventions. They explore the impact of different exercise modalities in reducing falls post-chemotherapy and how genetic factors influence strength training outcomes for survivors. The podcast highlights the unique health challenges faced by cancer survivors in the US.

Exploring the use of Plasma Growth Hormone as a potential biomarker for response to standard therapies in advanced liver cancer. Researchers identified a significant gap in research on biomarkers and conducted a study to explore this further. The study aims to shed light on current screening challenges and standard therapies for advanced hepatocellular carcinoma patients.

The podcast discusses the correlation between p-STAT3, c-Myc, and P2-HNF4α expression in nonalcoholic fatty liver disease. It explores the potential of these factors as biomarkers for assessing hepatocellular carcinoma risk in NAFLD patients. The chapter also delves into the relationships between gene expressions in NAFLD, highlighting the associations of p-STAT3 with hypertension and c-Myc with obesity, diabetes, and advanced fibrosis.

Researchers Yuji Morine, Tohru Utsunomiya, and Hisami Yamanaka-Okumura discuss using metabolomics to identify potential biomarkers for diagnosing Hepatocellular Carcinoma. Key findings include essential amino acids like leucine, valine, and tryptophan as promising indicators for HCC diagnosis.

The podcast delves into the intriguing world of Myeloid-Derived Suppressor Cells, discussing their role in cancer immunotherapy, their immunosuppressive activities, and potential manipulation for cancer treatment.

Researchers explore the overlooked potential of discarded genomic and transcriptomic data from cancer research, uncovering valuable strategies for understanding carcinogenesis and identifying clinical biomarkers.

Discover how APOE genotype affects cancer survivors' response to exercise intervention, influencing side effects severity and exercise outcomes in female post-treatment survivors, with a focus on lifestyle factors mitigating genetic impact.

Exploring the impact of CR EBBP mutations on disease-free survival rates in newly diagnosed Germinal Center Aggressive B Cell Lymphomas through mutation analysis on tumor biopsies.

Explore the use of predictive biomarkers in neoadjuvant chemotherapy for bladder cancer, highlighting the importance of personalized treatment. Discover the role of tumor and host biomarkers in identifying patients who will benefit most from chemotherapy. Uncover significant gene sets and molecular pathways that can predict responses to neoadjuvant chemotherapy in muscle invasive bladder cancer.

Discover how the CDK8 inhibitor MK256 shows promising antitumor activity in AML by inducing differentiation, inhibiting proliferation, and downregulating the STAT pathway. Researchers from UCSF and Touro University explore the potential of MK256 in treating AML based on their latest study.